首页 药物不良反应杂志 2025年27卷03期 静脉铁剂的临床应用和药学监护专家共识（2024）
药物不良反应杂志
期刊首页
过刊列表
高级检索
稿件发表
• 标准与规范 •
ENGLISH ABSTRACT
静脉铁剂的临床应用和药学监护专家共识（2024）
中国药理学会药源性疾病学专业委员会
广东省药学会
作者及单位信息
·
DOI： 10.3760/cma.j.cn114015-20240929-00070
Expert consensus of clinical application and pharmaceutical care for intravenous iron agents (2024)
Chinese Pharmacological Society Professional Committee of Drug-induced Diseases
Guangdong Pharmaceutical Association
Chen Xiao
Tang Kejing
Authors Info & Affiliations
Chinese Pharmacological Society Professional Committee of Drug-induced Diseases
Guangdong Pharmaceutical Association
Chen Xiao
Department of Pharmacy, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
Tang Kejing
Department of Respiratory and Critical Care, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
·
DOI： 10.3760/cma.j.cn114015-20240929-00070
0
0
0
0
0
0
扫描转手机阅读
下载中华医学期刊APP阅读更流畅 体验更丰富
PDF下载
APP内阅读
摘要
铁缺乏是导致贫血最常见的原因。静脉铁剂是治疗铁缺乏和缺铁性贫血的常用药物，常用于慢性肾脏病、心力衰竭、炎症性肠病、围手术期、肿瘤、妊娠哺乳期贫血患者的治疗。为了提高静脉铁剂合理使用和药学监护水平，中国药理学会药源性疾病学专业委员会和广东省药学会组织医学、药学、护理、医院管理等专业的专家共同研讨，检索国内外文献，收集循证医学证据，根据不同静脉铁剂的差异、临床应用情况和安全性制定本共识，为静脉铁剂的临床应用和药学监护提供依据。
铁;输注，静脉内;贫血;共识;药学监护
ABSTRACT
Iron deficiency is the most common cause of anemia. Intravenous iron is a common therapeutic drug for iron deficiency and iron deficiency anemia, which is commonly used in the treatment of anemia patients with chronic kidney disease, heart failure, inflammatory bowel disease, and cancer, as well as anemia patients in perioperative period and during pregnancy and lactation. In order to strengthen the rational use of intravenous iron and improve the pharmaceutical care level, the Chinese Pharmacological Society Professional Committee of Drug-induced Diseases and the Guangdong Pharmaceutical Association organized experts majoring in medicine, pharmacy, nursing, hospital mana- gement and other specialties to develop this consensus through discussing, retrieving domestic and foreign literature, and collecting evidence-based medical evidence. The differences among intravenous iron agents, clinical situations of application, and the safety issues are considered in the consensus, in order to provide the basis for the rational application and pharmaceutical care in clinic.
Iron;Infusions, intravenous;Anemia;Consensus;Pharmaceutical care
Chen Xiao, Department of Pharmacy, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China, Email:
mocdef.labiamtohnehcywknarf;
Tang Kejing, Department of Respiratory and Critical Care, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China, Email:
nc.defudabe.usys.liamjkgnat
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文
中国药理学会药源性疾病学专业委员会,广东省药学会. 静脉铁剂的临床应用和药学监护专家共识（2024）[J]. 药物不良反应杂志,2025,27(03)：129-141.
DOI:10.3760/cma.j.cn114015-20240929-00070PERMISSIONS
Request permissions for this article from CCC.
评价本文
*以上评分为匿名评价
本文评分
5分
[累计个]
向我们报错
版权归中华医学会所有。
未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。
除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
铁缺乏是引起贫血最常见的原因。流行病学研究结果显示，2021年全球贫血患病率为24.3%，相当于19.2亿的流行病例；育龄期女性（15~49岁）受月经和分娩的影响，贫血和铁缺乏的患病率显著高于同年龄段男性（33.7%比11.3%）；中国贫血的患病率约12.4%
[
1
]。世界卫生组织和儿童基金会呼吁，2030年要将育龄期女性的贫血患病率降低50%，以达到可持续发展、改善营养及促进健康等目标
[
2
]。
补铁是铁缺乏和缺铁性贫血的常规治疗方法，根据给药途径可分为口服铁剂和静脉铁剂，其中补充静脉铁剂是治疗缺铁性贫血和其他铁缺乏相关疾病的重要手段。目前静脉铁剂的临床应用及药学监护尚未受到足够的重视，亟需一个基于循证支持的指导性文件，特此制定本共识。中国药理学会药源性疾病学专业委员会和广东省药学会基于当前静脉铁剂的临床研究和应用现状，组织药学、临床医学、护理、医院管理、循证医学等多学科专家，制定《静脉铁剂临床应用和药学监护专家共识》。该共识主要涉及静脉铁剂的7个临床问题，包括：静脉铁剂在慢性肾脏病（chronic kidney disease，CKD）、心力衰竭（心衰）、炎症性肠病（inflammatory bowel diseases，IBD）、围手术期、肿瘤、妊娠哺乳期患者的临床应用和静脉铁剂的药学监护。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
已是订阅账户?
登录
参考文献
[1]
GBD 2021 Anaemia Collaborators. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990―2021: findings from the Global Burden of Disease Study 2021[J]. Lancet Haematol, 2023,10(9):e713-e734. DOI:
10.1016/S2352-3026(23)00160-6
.
[2]
WHO/UNICEF Discussion Paper. The extension of the 2025 maternal, infant and young child nutrition targets to 2030[EB/OL]. ( 2021-05-12) [2024-06-06]. https://data.unicef.org/resources/extension-of-2025-maternal-infant-young-child-nutrition-targets-2030/.
[3]
Lucas S , Garg M . Intravenous iron: an update[J]. Intern Med J, 2024,54(1):26-34. DOI:
10.1111/imj.16184
.
[4]
Macdougall IC , White C , Anker SD ,et al. Intravenous iron in patients undergoing maintenance hemodialysis[J]. N Engl J Med, 2019,380(5):447-458. DOI:
10.1056/NEJMoa1810742
.
[5]
Richardson D , Bartlett C , Jolly H ,et al. Intravenous iron for CAPD populations: proactive or reactive strategies？[J]. Nephrol Dial Transplant, 2001,16(1):115-119. DOI:
10.1093/ndt/16.1.115
.
[6]
Macdougall IC , Bock AH , Carrera F ,et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia[J]. Nephrol Dial Transplant, 2014,29(11):2075-2084. DOI:
10.1093/ndt/gfu201
.
[7]
Babitt JL , Eisenga MF , Haase VH ,et al. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference[J]. Kidney Int, 2021,99(6):1280-1295. DOI:
10.1016/j.kint.2021.03.020
.
[8]
《铁剂在慢性肾脏病贫血患者中应用的临床实践指南》编写委员会. 铁剂在慢性肾脏病贫血患者中应用的临床实践指南[J]. 中国血液净化, 2022,21增刊:17-40. DOI:
10.3969/j.issn.1671-4091.2022.S.002
.
Committee of Clinical Practice Guideline for Use of Iron on Anemia in Chronic Kidney Disease. Clinical practice guideline for use of iron on anemia in chronic kidney disease[J]. Chin J Blood Purif, 2022,21:Suppl-17. 40DOI:
10.3969/j.issn.1671-4091.2022.S.002
.
[9]
European Society of Cardiology. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2024,26(1):5-17. DOI:
10.1002/ejhf.3024
.
[10]
Mentz RJ , Garg J , Rockhold FW ,et al. Ferric carboxymaltose in heart failure with iron deficiency[J]. N Engl J Med, 2023,389(11):975-986. DOI:
10.1056/NEJMoa2304968
.
[11]
Ponikowski P , Kirwan BA , Anker SD ,et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial[J]. Lancet, 2020,396(10266):1895-1904. DOI:
10.1016/S0140-6736(20)32339-4
.
[12]
Kalra PR , Cleland J , Petrie MC ,et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial[J]. Lancet, 2022,400(10369):2199-2209. DOI:
10.1016/S0140-6736(22)02083-9
.
[13]
Sephien A , Dayto DC , Reljic T ,et al.
Efficacy of in
travenous iron in patients with heart failure with reduced ejection fraction and iron deficiency: a systematic review and meta-analysis of randomized control trials
[J]. Am J Cardiovasc Drugs, 2024,24(2):285-302. DOI:
10.1007/s40256-024-00635-7
.
[14]
Gordon M , Sinopoulou V , Iheozor-Ejiofor Z ,et al. Interventions for treating iron deficiency anaemia in inflammatory bowel disease[J]. Cochrane Database Syst Rev, 2021,1(1):CD0135 29. DOI:
10.1002/14651858.CD013529.pub2
.
[15]
Lee T , Clavel T , Smirnov K ,et al.
Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IB
D
[J]. Gut, 2017,66(5):863-871. DOI:
10.1136/gutjnl-2015-309940
.
[16]
Kangaspunta M , Haapamäki J , Färkkilä M ,et al. Inflammatory bowel disease and anemia: intravenous iron treatment[J]. Scand J Gastroenterol, 2018,53(4):430-434. DOI:
10.1080/00365521.2018.1441435
.
[17]
García-López S , Bocos JM , Gisbert JP ,et al. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life[J]. Blood Transfus, 2016,14(2):199-205. DOI:
10.2450/2016.0246-15
.
[18]
Zoller H , Wolf M , Blumenstein I ,et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial[J]. Gut, 2023,72(4):644-653. DOI:
10.1136/gutjnl-2022-327897
.
[19]
Dignass AU , Gasche C , Bettenworth D ,et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases[J]. J Crohns Colitis, 2015,9(3):211-222. DOI:
10.1093/ecco-jcc/jju009
.
[20]
Richards T , Breymann C , Brookes MJ ,et al. Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice[J]. Ann Med, 2021,53(1):274-285. DOI:
10.1080/07853890.2020.1867323
.
[21]
Aksan A , Işık H , Radeke HH ,et al. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2017,45(10):1303-1318. DOI:
10.1111/apt.14043
.
[22]
Elhenawy AM , Meyer SR , Bagshaw SM ,et al. Role of preoperative intravenous iron therapy to correct anemia before major surgery: a systematic review and meta-analysis[J]. Syst Rev, 2021,10(1):36. DOI:
10.1186/s13643-021-01579-8
.
[23]
Schack A , Berkfors AA , Ekeloef S ,et al. The effect of perioperative iron therapy in acute major non-cardiac surgery on allogenic blood transfusion and postoperative haemoglobin levels: a systematic review and meta-analysis[J]. World J Surg, 2019,43(7):1677-1691. DOI:
10.1007/s00268-019-04971-7
.
[24]
Talboom K , Borstlap W , Roodbeen SX ,et al. Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): a multicentre, open-label, randomised, controlled trial[J]. Lancet Haematol, 2023,10(4):e250-e260. DOI:
10.1016/S2352-3026(22)00402-1
.
[25]
Shander A , Corwin HL , Meier J ,et al. Recommendations from the international consensus conference on anemia management in surgical patients (ICCAMS)[J]. Ann Surg, 2023,277(4):581-590. DOI:
10.1097/SLA.0000000000005721
.
[26]
Muñoz M , Acheson AG , Auerbach M ,et al. International consensus statement on the peri-operative management of anaemia and iron deficiency[J]. Anaesthesia, 2017,72(2):233-247. DOI:
10.1111/anae.13773
.
[27]
Perelman I , Winter R , Sikora L ,et al. The efficacy of postoperative iron therapy in improving clinical and patient-centered outcomes following surgery: a systematic review and meta-analysis[J]. Transfus Med Rev, 2018,32(2):89-101. DOI:
10.1016/j.tmrv.2017.10.002
.
[28]
Khalafallah AA , Yan C , Al-Badri R ,et al. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial[J]. Lancet Haematol, 2016,3(9):e415-e425. DOI:
10.1016/S2352-3026(16)30078-3
.
[29]
Yoon HM , Kim YW , Nam BH ,et al. Intravenous iron supplementation may be superior to observation in acute isovolemic anemia after gastrectomy for cancer[J]. World J Gastroenterol, 2014,20(7):1852-1857. DOI:
10.3748/wjg.v20.i7.1852
.
[30]
Bisbe E , Moltó L ,
<x>Arro</x>
<x>yo</x>
R ,et al. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty[J]. Br J Anaesth, 2014,113(3):402-409. DOI:
10.1093/bja/aeu092
.
[31]
Froessler B , Palm P , Weber I ,et al. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial[J]. Ann Surg, 2016,264(1):41-46. DOI:
10.1097/SLA.0000000000001646
.
[32]
Auerbach M , Ballard H , Trout JR ,et al.
Intravenous iron optimizes th
e response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial
[J]. J Clin Oncol, 2004,22(7):1301-1307. DOI:
10.1200/JCO.2004.08.119
.
[33]
Auerbach M , Silberstein PT , Webb RT ,et al. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia[J]. Am J Hematol, 2010,85(9):655-663. DOI:
10.1002/ajh.21779
.
[34]
Bastit L , Vandebroek A , Altintas S ,et al.
Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or
without intravenous iron in patients with chemotherapy-induced anemia
[J]. J Clin Oncol, 2008,26(10):1611-1618. DOI:
10.1200/JCO.2006.10.4620
.
[35]
Hedenus M , Birgegård G , Näsman P ,et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study[J]. Leukemia, 2007,21(4):627-632. DOI:
10.1038/sj.leu.2404562
.
[36]
Henry DH , Dahl NV , Auerbach M ,et al.
Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with
cancer receiving chemotherapy
[J]. Oncologist, 2007,12(2):231-242. DOI:
10.1634/theoncologist.12-2-231
.
[37]
Pedrazzoli P , Farris A , Del Prete S ,et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha[J]. J Clin Oncol, 2008,26(10):1619-1625. DOI:
10.1200/JCO.2007.12.2051
.
[38]
Steinmetz T , Tschechne B , Harlin O ,et al. Clinical experience with ferric carboxymaltose in the treatment of cancer-and chemotherapy-associated anaemia[J]. Ann Oncol, 2013,24(2):475-482. DOI:
10.1093/annonc/mds338
.
[39]
Birgegård G , Henry D , Glaspy J ,et al. A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: the PROFOUND trial[J]. Pharmacotherapy, 2016,36(4):402-414. DOI:
10.1002/phar.1729
.
[40]
中华医学会血液学分会红细胞疾病（贫血）学组. 静脉铁剂应用中国专家共识（2019年版）[J]. 中华血液学杂志, 2019,40(5):358-362. DOI:
10.3760/cma.j.issn.0253-2727.2019.05.002
.
Red Blood Cell Diseases (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the application of intravenous iron (2019)[J]. Chin J Hematol, 2019,40(5):358-362. DOI:
10.3760/cma.j.issn.0253-2727.2019.05.002
.
[41]
Leung TW , Damodaran P , Torres R ,et al. Expert consensus on improving iron deficiency anemia management in obstetrics and gynecology in Asia[J]. Int J Gynaecol Obstet, 2023,163(2):495-509. DOI:
10.1002/ijgo.14804
.
[42]
European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines[EB/OL]. ( 2013-06-28) [2023-12-12].
https://www.ema.europa.eu/en/news/new-recommendations-m
anage-risk-allergic-reactions-intravenous-iron-containing-medicines
.
[43]
Govindappagari S , Burwick R M . Treatment of iron deficiency anemia in pregnancy with intravenous versus oral iron: systematic review and meta-analysis[J]. Am J Perinatol, 2019,36(4):366-376. DOI:
10.1055/s-0038-1668555
.
[44]
Lewkowitz A K , Gupta A , Simon L ,et al. Intravenous compared with oral iron for the treatment of iron-deficiency anemia in pregnancy: a systematic review and meta-analysis[J]. J Perinatol, 2019,39(4):519-532. DOI:
10.1038/s41372-019-0320-2
.
[45]
Sultan P , Bampoe S , Shah R ,et al.
Oral
vs
intravenous iron therapy for postpartum anemia: a systematic review and meta-analysis
[J]. Am J Obstet Gynecol, 2019,221(1):19-29. DOI:
10.1016/j.ajog.2018.12.016
.
[46]
Auerbach M , James SE , Nicoletti M ,et al. Results of the first american prospective study of intravenous iron in oral iron-intolerant iron-deficient gravidas[J]. Am J Med, 2017,130(12):1402-1407. DOI:
10.1016/j.amjmed.2017.06.025
.
[47]
Rogozińska E , Daru J , Nicolaides M ,et al. Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis[J]. Lancet Haematol, 2021,8(7):e503-e512. DOI:
10.1016/S2352-3026(21)00137-X
.
[48]
Vanobberghen F , Lweno O , Kuemmerle A ,et al. Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial[J]. Lancet Glob Health, 2021,9(2):e189-e198. DOI:
10.1016/S2214-109X(20)30448-4
.
[49]
Pasricha SR , Mwangi MN , Moya E ,et al. Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trial[J]. Lancet, 2023,401(10388):1595-1609. DOI:
10.1016/S0140-6736(23)00278-7
.
[50]
Van Wyck DB , Martens MG , Seid MH ,et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial[J]. Obstet Gynecol, 2007,110(2):Pt 1-267. 278DOI:
10.1097/01.AOG.0000275286.03283.18
.
[51]
Elmore C , Ellis J . Screening, Treatment, and monitoring of iron deficiency anemia in pregnancy and postpartum[J]. J Midwifery Womens Health, 2022,67(3):321-331. DOI:
10.1111/jmwh.13370
.
[52]
Holm C , Thomsen LL , Langhoff-Roos J . Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage[J]. J Matern Fetal Neonatal Med, 2019,32(17):2797-2804. DOI:
10.1080/14767058.2018.1449205
.
[53]
Saad AF , Stepanek R , Kothmann M ,et al. Intravenous iron compared with oral iron supplementation for the treatment of postpartum anemia: a randomized controlled trial[J]. Obstet Gynecol, 2023,141(6):1052-1055. DOI:
10.1097/AOG.0000000000005143
.
[54]
Seid MH , Derman RJ , Baker JB ,et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial[J]. Am J Obstet Gynecol, 2008,199(4):435.e1-e7. DOI:
10.1016/j.ajog.2008.07.046
.
[55]
Holm C , Thomsen LL , Norgaard A ,et al. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial[J]. Vox Sang, 2017,112(3):219-228. DOI:
10.1111/vox.12477
.
[56]
Ganzoni AM . Intravenous iron-dextran: therapeutic and experimental possibilities[J]. Schweiz Med Wochenschr, 1970,100(7):301-303. DOI:
10.1007/s11214-010-9636-0
.
[57]
[58]
Stefanova D , Raychev A , Deville J ,et al. Hepcidin protects against lethal escherichia coli sepsis in mice inoculated with isolates from septic patients[J]. Infect Immun, 2018,86(7):e00253-e00218. DOI:
10.1128/IAI.00253-18
.
[59]
Shah AA , Donovan K , Seeley C ,et al. Risk of infection associated with administration of intravenous iron: a systematic review and meta-analysis[J]. JAMA Netw Open, 2021,4(11):e2133935. DOI:
10.1001/jamanetworkopen.2021.33935
.
[60]
Salim SA , Cheungpasitporn W , Elmaraezy A ,et al. Infectious complications and mortality associated with the use of IV iron therapy: a systematic review and meta-analysis[J].
In
t Urol Nephrol
, 2019,51(10):1855-1865. DOI:
10.1007/s11255-019-02273-4
.
[61]
Michels KR , Zhang Z , Bettina AM ,et al. Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia[J]. JCI Insight, 2017,2(6):e92002. DOI:
10.1172/jci.insight.92002
.
[62]
Stefanova D , Raychev A , Arezes J ,et al. Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron[J]. Blood, 2017,130(3):245-257. DOI:
10.1182/blood-2017-03-772715
.
[63]
Arezes J , Jung G , Gabayan V ,et al.
Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium
Vibrio vulnificus
[J]. Cell Host Microbe, 2015,17(1):47-57. DOI:
10.1016/j.chom.2014.12.001
.
[64]
Kitsati N , Liakos D , Ermeidi E ,et al. Rapid elevation of transferrin saturation and serum hepcidin concentration in hemodialysis patients after intravenous iron infusion[J]. Haematologica, 2015,100(3):e80-e83. DOI:
10.3324/haematol.2014.116806
.
[65]
杭永付,朱红,缪丽燕. 静脉铁剂临床应用与监护[J]. 临床药物治疗杂志, 2022,20(12):24-28. DOI:
10.3969/j.issn.1672-3384.2022.12.005
.
Hang YF , Zhu H , Miao LY . Pharmaceutical care and clinical use of intravenous iron[J]. Clinical Medication Journal, 2022,20(12):24-28. DOI:
10.3969/j.issn.1672-3384.2022.12.005
.
[66]
Van Doren L , Steinheiser M , Boykin K ,et al.
Expert consen
sus guidelines: intravenous iron uses, formulations, administration, and management of reactions
[J]. Am J Hematol, 2024,99(7):1338-1348. DOI:
10.1002/ajh.27220
.
[67]
中国临床肿瘤学会指南工作委员会. 肿瘤相关性贫血临床实践指南2022[M]. 北京:人民卫生出版社, 2022:3-47.
Uidelines of Chinese Society of Clinical Oncology (CSCO). Clinical practice in tumor-related anemia[M]. Beijing:People′s Medical Publishing House, 2022:3-47.
[68]
Aapro M , Beguin Y , Bokemeyer C ,et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2018,29(Suppl 4):iv96-iv110. DOI:
10.1093/annonc/mdx758
.
[69]
Gordon H , Burisch J , Ellul P ,et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease[J]. J Crohns Colitis, 2024,18(1):1-37. DOI:
10.1093/ecco-jcc/jjad108
.
[70]
中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021,101(20):1463-1502. DOI:
10.3760/cma.j.cn112137-20210201-00309
.
Working Group on Guidelines for Renal Anemia of the Nephrology Branch of the Chinese Medical Association.
Clinical practice guidelines
for diagnosis and treatment of renal anemia in China
[J]. Natl Med J China, 2021,101(20):1463-1502. DOI:
10.3760/cma.j.cn112137-20210201-00309
.
[71]
Chertow GM , Mason PD , Vaage-Nilsen O ,et al. Update on adverse drug events associated with parenteral iron[J]. Nephrol Dial Transplant, 2006,21(2):378-382. DOI:
10.1093/ndt/gfi253
.
[72]
Dave CV , Brittenham GM , Carson JL ,et al. Risks for anaphylaxis with intravenous iron formulations: a retrospective cohort study[J]. Ann Intern Med, 2022,175(5):656-664. DOI:
10.7326/M21-4009
.
[73]
Kennedy NA , Achebe MM , Biggar P ,et al. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose[J]. Int J Clin Pharm, 2023,45(3):604-612. DOI:
10.1007/s11096-023-01548-2
.
[74]
Fortuny J , von Gersdorff G , Lassalle R ,et al. Use of intravenous iron and risk of anaphylaxis: a multinational observational post-authorisation safety study in Europe[J]. Pharmacoepidemiol Drug Saf, 2021,30(10):1447-1457. DOI:
10.1002/pds.5319
.
[75]
Arastu AH , Elstrott BK , Martens KL ,et al. Analysis of adverse events and intravenous iron infusion formulations in adults with and without prior infusion reactions[J]. JAMA Netw Open, 2022,5(3):e224488. DOI:
10.1001/jamanetworkopen.2022.4488
.
[76]
Lim W , Afif W , Knowles S ,et al. Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults[J]. Vox Sang, 2019,114(4):363-373. DOI:
10.1111/vox.12773
.
[77]
李晓桐,翟所迪,王强,等. 《严重过敏反应急救指南》推荐意见[J]. 药物不良反应杂志, 2019,21(2):85-91. DOI:
10.3760/cma.j.issn.1008-5734.2019.02.002
.
Li XT , Zhai SD , Wang Q ,et al. Recommendations in Guideline for Emergency Management of Anaphylaxis[J]. ADRJ, 2019,21(2):85-91. DOI:
10.3760/cma.j.issn.1008-5734.2019.02.002
.
[78]
Cardona V , Ansotegui IJ , Ebisawa M ,et al. World Allergy Organization anaphylaxis guidance 2020[J]. World Allergy Organ J, 2020,13(10):100472. DOI:
10.1016/j.waojou.2020.100472
.
[79]
Adkinson NF , Strauss WE , Macdougall IC ,et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial[J]. Am J Hematol, 2018,93(5):683-690. DOI:
10.1002/ajh.25060
.
[80]
Wolf M , Rubin J , Achebe M ,et al.
Effects of iron isomaltoside
vs
ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials
[J]. JAMA, 2020,323(5):432-443. DOI:
10.1001/jama.2019.22450
.
[81]
Emrich IE , Lizzi F , Siegel JD ,et al. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study[J]. BMC Med, 2020,18(1):178. DOI:
10.1186/s12916-020-01643-5
.
[82]
Schaefer B , Tobiasch M , Viveiros A ,et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside---a systematic review and meta-analysis[J]. Br J Clin Pharmacol, 2021,87(5):2256-2273. DOI:
10.1111/bcp.14643
.
[83]
Bellos I , Frountzas M , Pergialiotis V . Comparative risk of hypophosphatemia following the administration of intravenous iron formulations: a network meta-analysis[J]. Transfus Med Rev, 2020,34(3):188-194. DOI:
10.1016/j.tmrv.2020.07.002
.
[84]
Glaspy JA , Lim-Watson MZ , Libre MA ,et al. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review[J]. Ther Clin Risk Manag, 2020,16:245-259. DOI:
10.2147/TCRM.S243462
.
[85]
Auerbach M , Henry D , Derman RJ ,et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial[J]. Am J Hematol, 2019,94(9):1007-1014. DOI:
10.1002/ajh.25564
.
[86]
Schaefer B , Würtinger P , Finkenstedt A ,et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk[J]. PLoS One, 2016,11(12):e0167146. DOI:
10.1371/journal.pone.0167146
.
[87]
Frazier R , Hodakowski A , Cai X ,et al. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: a single-center prospective observational study of women with iron deficiency[J]. Bone, 2020,141:115559. DOI:
10.1016/j.bone.2020.115559
.
[88]
Rosano G , Schiefke I , Göhring UM ,et al. A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose[J]. J Clin Med, 2020,9(11):3587. DOI:
10.3390/jcm9113587
.
[89]
Schaefer B , Tobiasch M , Wagner S ,et al. Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management[J]. Bone, 2022,154:116202. DOI:
10.1016/j.bone.2021.116202
.
[90]
Wolf M , Chertow GM , Macdougall IC ,et al. Randomized trial of intravenous iron-induced hypophosphatemia[J]. JCI Insight, 2018,3(23):e124486. DOI:
10.1172/jci.insight.124486
.
[91]
Blumenstein I , Shanbhag S , Langguth P ,et al. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects---hypersensitivity, hypophosphatemia, and cardiovascular safety[J].
Expert Opin Drug
Saf
, 2021,20(7):757-769. DOI:
10.1080/14740338.2021.1912010
.
[92]
Decruyenaere A , Kortbeek K , Delanghe S ,et al. Incidence, evolution and risk factors of hypophosphatemia in patients with solid tumors receiving ferric carboxymaltose: a retrospective cohort study[J]. Acta Clin Belg, 2023,78(4):298-307. DOI:
10.1080/17843286.2022.2153465
.
[93]
Schaefer B , Zoller H , Wolf M . Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose[J]. J Clin Endocrinol Metab, 2022,107(4):1009-1019.
10.1210/clinem/dgab852
.
[94]
Boots J , Quax R . High-dose intravenous iron with either ferric carboxymaltose or ferric derisomaltose: a benefit-risk assessment[J]. Drug Saf, 2022,45(10):1019-1036. DOI:
10.1007/s40264-022-01216-w
.
[95]
Chen YJ , Lim C , McCormick J . Resistant iron-induced hypophosphatemia following colorectal surgery[J]. N Z Med J, 2019,132(1499):72-75.
[96]
Urbina T , Belkhir R , Rossi G ,et al. Iron supplementation-induced phosphaturic osteomalacia: FGF23 is the culprit[J]. J Bone Miner Res, 2018,33(3):540-542. DOI:
10.1002/jbmr.3369
.
[97]
Amarnani R , Travis S , Javaid MK . Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia[J]. Rheumatology (Oxford), 2020,59(8):2166-2168. DOI:
10.1093/rheumatology/kez627
.
[98]
Ramanathan G , Olynyk JK , Ferrari P . Diagnosing and preventing iron overload[J]. Hemodial Int, 2017,21(Suppl 1):S58-S67. DOI:
10.1111/hdi.12555
.
[99]
Hsu CC , Senussi NH , Fertrin KY ,et al. Iron overload disorders[J]. Hepatol Commun, 2022,6(8):1842-1854. DOI:
10.1002/hep4.2012
.
[100]
Hermitte-Gandoliere A , Petitpain N , Lepelley M ,et al. Cutaneous pigmentation related to intravenous iron extravasation: analysis from the French pharmacovigilance database[J]. Therapie, 2018,73(3):193-198. DOI:
10.1016/j.therap.2017.10.005
.
[101]
Lee W , Eun YS , Kim JY ,et al. Successful treatment of cutaneous siderosis using a 1064-nm Nd:YAG picosecond laser following intravenous iron extravasation: a case report[J]. J Cosmet Dermatol, 2024,23(10):3432-3433. DOI:
10.1111/jocd.16416
.
[102]
Heidemeyer K , Feldmeyer L , Raeber I ,et al. Successful treatment of iatrogenic cutaneous siderosis with pigment lasers: a retrospective study in 15 consecutive patients[J]. Acta Derm Venereol, 2020,100(10):adv00148. DOI:
10.2340/00015555-3503
.
备注信息
A
陈孝，中山大学附属第一医院药学部，广州 510080，Email：
mocdef.labiamtohnehcywknarf；
B
唐可京，中山大学附属第一医院呼吸与危重症医学科，广州 510080，Email：
nc.defudabe.usys.liamjkgnat
C
国际实践指南注册与透明化平台（PREPARE-2024CN668）
D
Practice Guideline Registration for Transparency (PREPARE-2024CN668)
E
所有作者声明不存在利益冲突
F
广东省医学科学技术研究基金 (C2020048、C2021039)
评论 （0条）
注册 登录
时间排序
- 时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
阿达木单抗致重度特应性皮炎继发多重耐药菌感染
曲敬蓉 等 药物不良反应杂志 2024,26(09)
阿达木单抗治疗Blau综合征1家系3例
王晨 等 中华皮肤科杂志 2024,57(06)
阿达木单抗治疗重度斑块状银屑病的临床观察
刘鸿伟 等 中华皮肤科杂志 2020,53(09)
阿达木单抗治疗重度银屑病14例临床疗效及安全性观察
张瑞丽 等 中华皮肤科杂志 2018,51(08)
分享
详细信息
表
访问与引文
阅读权限
参考文献
访问与引用
访问数据
0
0
全部时间 最近30天 最近6个月 最近12个月
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照
文献快照
N/A
N/A
AI总结中
N/A
N/A
快照内容由人工智能生成，供您参考。
你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。
0/50
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
0/2000
信息反馈
中文(简体)
英文
翻译
机器翻译功能由科大讯飞提供技术支持
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
你好！ 今天我能为您提供什么帮助？
0/30
of
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
扩写 缩写 改写 翻译
0/2000
信息反馈
历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大
翻译
润色
扩写
缩写
复制
引用
